Development and commercialisation
Biota and Daiichi Sankyo co-own a range of second generation influenza anti-virals, of which Inavir is the lead product.
Note the use of the phrase "is the lead product". There must be more to come. Toot Toot !
- Forums
- ASX - By Stock
- BTA
- relenza sales on the rise
relenza sales on the rise, page-3
-
- There are more pages in this discussion • 13 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)